Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2005 2
2006 2
2007 1
2008 5
2009 4
2010 4
2011 2
2012 2
2013 3
2014 2
2015 1
2016 2
2018 4
2019 9
2020 4
2021 2
2022 5
2023 3
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. Cappellini MD, et al. Among authors: voskaridou e. N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182. N Engl J Med. 2020. PMID: 32212518 Clinical Trial.
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.
Abboud MR, Cançado RD, De Montalembert M, Smith WR, Rimawi H, Voskaridou E, Güvenç B, Ataga KI, Keefe D, Grosch K, Watson J, Reshetnyak E, Nassin ML, Dei-Adomakoh Y. Abboud MR, et al. Among authors: voskaridou e. Lancet Haematol. 2025 Apr;12(4):e248-e257. doi: 10.1016/S2352-3026(24)00384-3. Epub 2025 Mar 12. Lancet Haematol. 2025. PMID: 40088922 Clinical Trial.
Novel Therapeutic Advances in β-Thalassemia.
Makis A, Voskaridou E, Papassotiriou I, Hatzimichael E. Makis A, et al. Among authors: voskaridou e. Biology (Basel). 2021 Jun 18;10(6):546. doi: 10.3390/biology10060546. Biology (Basel). 2021. PMID: 34207028 Free PMC article. Review.
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT, Cappellini MD, Kattamis A, Voskaridou E, Perrotta S, Piga AG, Filosa A, Porter JB, Coates TD, Forni GL, Thompson AA, Tartaglione I, Musallam KM, Backstrom JT, Esposito O, Giuseppi AC, Kuo WL, Miteva D, Lord-Bessen J, Yucel A, Zinger T, Shetty JK, Viprakasit V; BEYOND Investigators. Taher AT, et al. Among authors: voskaridou e. Lancet Haematol. 2022 Oct;9(10):e733-e744. doi: 10.1016/S2352-3026(22)00208-3. Epub 2022 Aug 22. Lancet Haematol. 2022. PMID: 36007538 Clinical Trial.
Cellular and biochemical heterogeneity contributes to the phenotypic diversity of transfusion-dependent β-thalassemia.
Theocharaki K, Anastasiadi AT, Delicou S, Tzounakas VL, Barla I, Rouvela S, Kazolia E, Tzafa G, Mpekoulis G, Gousdovas T, Pavlou E, Kostopoulos IV, Velentzas AD, Simantiris N, Xydaki A, Vassilaki N, Voskaridou E, Aggeli IK, Nomikou E, Tsitsilonis O, Papageorgiou E, Thomaidis N, Gikas E, Politou M, Komninaka V, Antonelou MH. Theocharaki K, et al. Among authors: voskaridou e. Blood Adv. 2025 May 13;9(9):2091-2107. doi: 10.1182/bloodadvances.2024015232. Blood Adv. 2025. PMID: 39928952 Free PMC article.
The effect of transfusion on immune responses in thalassemia.
Politou M, Komninaka V, Valsami S, Kapsimali V, Pouliakis A, Koutsouri T, Panayiotakopoulos G, Kotsianidis I, Voskaridou E. Politou M, et al. Among authors: voskaridou e. Blood Cells Mol Dis. 2020 Jul;83:102425. doi: 10.1016/j.bcmd.2020.102425. Epub 2020 Mar 31. Blood Cells Mol Dis. 2020. PMID: 32244102
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Cappellini MD, Taher AT, Piga A, Shah F, Voskaridou E, Viprakasit V, Porter JB, Hermine O, Neufeld EJ, Thompson AA, Tang D, Yucel A, Lord-Bessen J, Yu P, Guo S, Shetty JK, Miteva D, Zinger T, Backstrom JT, Oliva EN. Cappellini MD, et al. Among authors: voskaridou e. Eur J Haematol. 2023 Jul;111(1):113-124. doi: 10.1111/ejh.13975. Epub 2023 Apr 24. Eur J Haematol. 2023. PMID: 37095595 Clinical Trial.
60 results